论文部分内容阅读
许多研究表明,在动物模型上钙拮抗剂(CA)能减轻实验性动脉粥样硬化的严重程度。最近通过血管造影证实硝苯吡啶能减轻人体冠状动脉粥样硬化。动脉粥样硬化的主要过程包括脂质在动脉壁上聚积,平滑肌细胞移行至内膜并增殖和钙的聚积。对老一代CA(异搏停、硝苯吡啶、硫氮(?)酮)的研究表明CA可影响上述过程。但是,CA抗动脉粥样硬化的作用机制还有待进一步探讨。在扩大CA治疗应用范围的尝试中,第二代CA相继产生。这类新药在动物实验性
Numerous studies have shown that calcium antagonists (CA) reduce the severity of experimental atherosclerosis in animal models. Nifedipine has recently been shown to reduce coronary atherosclerosis in humans by angiography. The main processes of atherosclerosis include the accumulation of lipids on the arterial wall, migration of smooth muscle cells to the intima and proliferation and accumulation of calcium. Studies of older generation CA (verapamil, nifedipine, thiaminone) have shown that CA can affect the above process. However, CA anti-atherosclerosis mechanism remains to be further explored. In an attempt to broaden the range of CA treatments, second-generation CA was generated in succession. These new drugs are experimental in animals